first a our about brief, can thinking the had we're results I'll COVID-XX Thanks, of relatively detailed revenue quarter. keep Pete, to on more and good my comments has impact quarter discussion the second move so and we on profile morning. how the
basis to were the was XXXX. basis a on first end compared unchanged the well X. and quarter preliminary total $X.XX a as adverse our performance April an results declines the EPS a announced Adjusted year-over-year earnings decline were expectations the as at This COVID-XX. to revenues due First high on year. on representing of share per Both of basis of our $X.XX quarter guidance million, $XXX to last unfavorable to organic compared X.X% original of reported the revenue entirely impact on and were variance
saw of X.X% Slide advanced both and franchises. monitoring. Global review CSS CSF single-digit dural of and X, the were revenues the we million, quarter, an a slowdown with I'll reported both organic all to on in Despite low high start sales our neuro increase single-digit the growth We segment. neurosurgery an repair, on an basis. growth turn basis. Management you and Reported strong organic of energy X.XX% organic in was neurosurgery access $XXX at increased across growth end If
XX% Instruments basis. Sales in our organic an franchise on declined about
growth largest with previous late the softness we show early our decline as expectations, and did significant in to continue single-digit medical distributors in deferred line light through procedures. our office-based of typical orders their Instruments While March, March in see in dental low end-of-quarter
in We late also saw lighting capital purchases such the as surgical quarter. slow
advanced International in purchases first global by over sales markets, spread and including indirect digits precautionary COVID-XX. in several during single CSS in concerns were up China, to strength Japan due quarter, the of the high led
increased double at coming on by Moving year X. and our a Revenues in to Tissue basis. quarter, decline from the Sales Slide SurgiMend the AmnioExcel and in we OTT, or segment & capital supply facilities. Orthopedics $XXX the representing million, last were initiated of investments increase X.X% Boston Technologies, an organic Memphis our of driven digits on
Our broader for wound of last reconstructive the nonemergent the the weeks on through March. quarter treatment first regenerative X.X Most plastic and growth impacted procedure was while months low in portfolio took until were double-digit X deferrals us surgeries. COVID-XX-related track and of chronic
to were the saw reconstruction COVID-XX quarter, as digits private to business were in in single private In We Sales digits largely label in compared the quarter label increased line mid-single sales limited first quarter prior prescheduled. low with down orders year. impact expectations. total, our wound the in first in
growth year-over-year positive both U.S. COVID-XX-related markets deferrals in mid-March. down and seeing until nonemergent were our we orthopedics, in virtually procedures In international shut
products sales International sales digits based tissue in increased full quarter low early mid-single on Europe. For quarter, orthopedic in strength in the the single digits. OTT declined in
will XXXX. performance quarter review Adjusted cash gross was P&L to XX.X%, components. now I of Slide the from our quarter first and the unchanged Turning flow key X. margin first of
compared prior to margin in adjusted the Our XX.X% EBITDA was XX.X% year.
in quarter year. year. quarter share in per compared $X.XX first were compared $X.XX prior the to First share to earnings Adjusted the $X.XX $X.XX per earnings were GAAP last
were to revenue revenue an COVID-XX, caused expectations. decreases were nonemergent U.S. This EBITDA primarily resulted procedures compared decline growth in deferred, international our in as original unfavorable primarily lower-than-expected in The and margin revenues, gross in to surgical related U.S. relative to margin which the gross in
spending -- rate same our blended by related to were SG&A and contributed in R&D revenue and EPS down a factors. as the levels well COVID-related lower the tax higher relative Additionally, as to decline
share repurchase slightly outstanding total expected February, Diluted shares the due initiate program. were be program agreement. share first XX% In delivered. an quarter, did under down year-over-year accelerated to in the Recall repurchased of that the early to repurchase the approximately we were shares
both about Operating year, which million $XX quarter, levels, by first million flow in last than was lower inventory earnings lower were of COVID-XX. cash by the higher and $X impacted adversely driven
organization. have during expenses. this cash the a preserve revenue We structure in we more Before estimate chart, taken leave expenses reduce In and including our to manage by let than actions elaborate the announced cost period about this reductions XX% I April, operating on total, will these XX% steps me reduction variable sweeping our cost of across cost we instability. in
decreased have shape significantly recovery amounting some these our our to largely manufacturing an facilities, actions to the reduced but duration in the depend overall on will hours also likely reduction The capital quarter. third will expenditures. We've of last of XX%. of We revenue XX% of into
the of time, the for with second we and in in low quarter. have and deliberate decline prioritization actions lower improves. company is certain ensure to and sharp R&D critical significant we capital, growth revenues, these programs margins cost same expected clinical very At been positioned supply regenerative of expect products on the the the with environment EBITDA our as single-digit profitability Even the
X.Xx. to allowable provide debt its of bank billion at ended a March and you capital the of to leverage XX. Slide quarter as under I'll approximately maximum the our consolidated June ratio The structure We agreement net remains turn update of of XXXX. total $X.X leverage with brief Xx company's through ratio credit If X,
have on and June due we XXXX. credit not cash our revolver. does until company undrawn facility $XXX and million The equivalents Importantly, principal repayments of cash have billion any of $X.XX
for the in revenue how If environment the about you scenarios second context to likely think current of and turn profile Slide into our insight you quarter. the XX, to COVID-XX some provide I'll revenue
guidelines, pandemic and have talking our of and deferrable recommending This period. procedures certain data various the our urgent plot the on enabled procedures. to where surgical the surgical this fall has urgent, during products reviewed moderately spectrum deferral us have more more We elective of customers been to throughout
illustrates slide thinking on our following The information. current available based
urgent procedures longer provide a right, boxes that skew to the to scale attempted that be procedures, left, a have with skewed into slightly We can more period. are the those qualitative deferred and indicating for the
many orthopedic basis. procedures a budgets purchases, Traumatic to capital and acute elective to brain typically hospital are and urgent deferred are longer. are Extremity more be injuries treated expected and burns doing tied which wounds on more are
broader much patient-specific in more wider category, the time can for must many the to that moderately from of Also, patient. serious variables, deferred be underlying to used which it's range of are environment urgent for our analyzing the period considered. remember without only the outcome be set of important products a In a conditions which of short risk hospital
provide who we're about I'd Now like call how thinking the over some turn will and insights recovery. to to Glenn, additional Glenn?